PP
TNGX icon

Paloma Partners’s Tango Therapeutics TNGX Stock Holding History

Paloma Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,040
Closed -$79.7K – 1464
2024
Q1 		$79.7K Buy
+10,040
New +$108K ﹤0.01% 675

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Paloma Partners's TNGX Position: Q2 2024 in Review

Paloma Partners sold out of Tango Therapeutics (TNGX) in Q2 2024, closing a stake of 10,040 shares — an estimated $79.7K sold.

Paloma Partners first reported a position in TNGX in Q1 2024 and held it in 1 quarter. The position peaked at $79.7K in Q1 2024. 119 funds tracked by Wall St. Rank hold TNGX as of Q2 2024.

  • Paloma Partners reported no remaining Tango Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paloma Partners sold 10,040 Tango Therapeutics shares in Q2 2024, an estimated $79.7K.
  • Paloma Partners first reported a position in Tango Therapeutics in Q1 2024 and held it in 1 quarter.
  • Paloma Partners's Tango Therapeutics position peaked at $79.7K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2024.

Based on Paloma Partners's 13F filing for Q2 2024, filed 14 Aug 2024.